EIF4E OVEREXPRESSION AND BREAST CANCER RECURRENCE

研究人员建议确定真核启动因子4E， 它帮助RNA解旋酶与51个未翻译的信使核糖核酸区域结合。 在细胞系中过度表达会产生恶性表型。在……里面 初步研究，通过Western印迹确定发生了过度表达 在乳腺癌中，但在良性乳腺病变中不是。初步数据 也将过度表达的程度与肿瘤的侵袭性联系起来 和生存。然而，这些初步研究是基于小规模的 数字。因此，研究人员建议进行一项前瞻性研究 在168名患有II或III期乳腺癌的妇女中。他们的首要目标是 评估eIF4E在乳腺组织中的过度表达，他们的第二个目标是 执行ER和PR分析，以便能够将此数据与 EIF4E。他们相信，5年后，他们将拥有足够的 确定过度表达是否与 复发。调查人员认为，这些数据可能会导致更多 关于谁需要化疗的知情决定，即通过 暗示如果eIF4E是II期复发的预测，那么 这也可能是第一阶段。然后，一项更大规模的研究 足够的力量确定I期乳腺癌的复发 将被证明是正当的。

The investigators propose to determine eukaryotic initiation factor 4E, which assists RNA helicases to bind to 51 untranslated regions of mRNA. Overexpression in cell lines produces a malignant phenotype. In preliminary studies, overexpression determined by Western blot occurs in breast cancers, but not in benign breast lesions. Preliminary data also associates the degree of overexpression with tumor aggressiveness and survival. However, these preliminary studies are based on small numbers. Thus, the investigators propose to perform a prospective study of 168 women with stage II or III breast cancer. Their first aim is to assess eIF4E overexpression in breast tissue, and their second aim is to perform ER and PR analysis so as to be able to relate this data to the eIF4E. They believe that in 5 years, they will have enough statistical power to determine if overexpression is associated with recurrence. The investigators believe that this data might lead to more informed decisions regarding who needs chemotherapy, i.e., by implication that if eIF4E is predictive of recurrence in stage II, then it might be for stage I as well. Then, a much larger study with sufficient power for determining recurrence in stage I breast cancer will be justified.